---
title: "Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Pharmacology questions"
description: "Pharmacology questions on Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Components, Mechanism, and Pharmacokinetics. Questions: What is in Biktarvy? What are the inactive ingredients in Biktarvy? How does Biktarvy work (mechanism of action)? How is Biktarvy metabolized and eliminated? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Pharmacology questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Biktarvy](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf)

## Components

<a id="biktarvy-components"></a>

### What is in Biktarvy?

> “BIKTARVY is a three-drug fixed dose combination product containing bictegravir (BIC), 
> emtricitabine (FTC), and tenofovir alafenamide (TAF).”

Source: [BIKTARVY: Prescribing information, page 4, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=4)

> “BIC is an integrase strand transfer inhibitor (INSTI). 
> • FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse 
> transcriptase inhibitor (HIV NRTI).  
> • TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside 
> phosphonate (nucleotide) analog of adenosine 5′-monophosphate.”

Source: [BIKTARVY: Prescribing information, page 19, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=19)

> “BIKTARVY tablets are available in two dose strengths: 
> • 50 mg/200 mg/25 mg tablets: 50 mg of bictegravir (BIC) (equivalent to 52.5 mg of 
> bictegravir sodium), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir 
> alafenamide (TAF) (equivalent to 28 mg of tenofovir alafenamide fumarate). 
> These tablets are purplish brown, capsule-shaped, film-coated, and debossed 
> with “GSI” on one side and “9883” on the other side. 
> • 30 mg/120 mg/15 mg tablets: 30 mg of BIC (equivalent to 31.5 mg of bictegravir 
> sodium), 120 mg of FTC, and 15 mg of TAF (equivalent to 16.8 mg of tenofovir 
> alafenamide fumarate). These tablets are pink, capsule-shaped, film-coated, and 
> either debossed with “GSI” on one side and “B”  on the other side; or with a non- 
> functional bisecting score line on one side and “BVY” on the other side.”

Source: [BIKTARVY: Prescribing information, page 5, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=5)

<a id="biktarvy-inactive-ingredients"></a>

### What are the inactive ingredients in Biktarvy?

> “Both dose strengths of BIKTARVY tablets include the following inactive ingredients: 
> croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets 
> for both dose strengths are film-coated with a coating material containing iron oxide 
> black, iron oxide red, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.”

Source: [BIKTARVY: Prescribing information, page 20, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=20)

## Mechanism

<a id="biktarvy-mechanism"></a>

### How does Biktarvy work (mechanism of action)?

> “Bictegravir: BIC inhibits the strand transfer activity of HIV-1 integrase (integrase 
> strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme that is required for viral 
> replication. Inhibition of integrase prevents the integration of linear HIV-1 DNA into 
> host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of 
> the virus.  
> Emtricitabine: FTC, a synthetic nucleoside analog of cytidine, is phosphorylated by 
> cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate 
> inhibits the activity of the HIV-1 RT by competing with the natural substrate 
> deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA 
> which results in chain termination. Emtricitabine 5′-triphosphate is a weak inhibitor of 
> mammalian DNA polymerases α, β, Ɛ, and mitochondrial DNA polymerase γ.”

Source: [BIKTARVY: Prescribing information, page 30, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=30)

> “Tenofovir Alafenamide: TAF is a phosphonamidate prodrug of tenofovir 
> (2′-deoxyadenosine monophosphate analog). Plasma exposure to TAF allows for 
> permeation into cells and then TAF is intracellularly converted to tenofovir through 
> hydrolysis by cathepsin A. Tenofovir is subsequently phosphorylated by cellular 
> kinases to the active metabolite tenofovir diphosphate. Tenofovir diphosphate 
> inhibits HIV-1 replication through incorporation into viral DNA by the HIV RT, which 
> results in DNA chain-termination. Tenofovir diphosphate is a weak inhibitor of 
> mammalian DNA polymerases that include mitochondrial DNA polymerase γ and 
> there is no evidence of toxicity to mitochondria in cell culture.”

Source: [BIKTARVY: Prescribing information, page 31, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=31)

## Pharmacokinetics

<a id="biktarvy-metabolism"></a>

### How is Biktarvy metabolized and eliminated?

> “Pharmacokinetic Properties of the Components of BIKTARVY  
>
> Bictegravir (BIC) 
> Emtricitabine (FTC) 
> Tenofovir 
> Alafenamide (TAF)”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

> “Metabolic pathway(s) 
> CYP3A 
> UGT1A1 
> Not significantly 
> metabolized 
> Cathepsin A<sup>d</sup> 
> (PBMCs) 
> CES1 (hepatocytes) 
> Excretion 
> Major route of elimination 
> Metabolism  
> Glomerular filtration 
> and active tubular 
> secretion 
> Metabolism  
> % of dose excreted in urine<sup>e</sup> 
> 35 
> 70 
> <1 
> % of dose excreted in feces<sup>e</sup> 
> 60.3 
> 13.7 
> 31.7”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

> “PBMCs=peripheral blood mononuclear cells; CES1=carboxylesterase 1”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

> “In vivo, TAF is hydrolyzed within cells to form tenofovir (major metabolite), which is phosphorylated to the active 
> metabolite, tenofovir diphosphate. In vitro studies have shown that TAF is metabolized to tenofovir by cathepsin A 
> in PBMCs and macrophages; and by CES1 in hepatocytes.”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

> “e.  Dosing in mass balance studies: single dose administration of [<sup>14</sup>C] BIC; single dose administration of [<sup>14</sup>C] FTC  
> after multiple dosing of FTC for ten days; single dose administration of [<sup>14</sup>C] TAF.”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

Note: Each row of Table 4 lists values in header order: bictegravir (BIC), emtricitabine (FTC), then tenofovir alafenamide (TAF).

<a id="biktarvy-half-life"></a>

### What is the half-life of Biktarvy?

> “Pharmacokinetic Properties of the Components of BIKTARVY  
>
> Bictegravir (BIC) 
> Emtricitabine (FTC) 
> Tenofovir 
> Alafenamide (TAF)”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

> “t1/2 (h)<sup>c</sup> 
> 17.3 (14.8, 20.7) 
> 10.4 (9.0, 12.0) 
> 0.51 (0.45, 0.62)<sup>c</sup>”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

> “c. t1/2 values refer to median (Q1, Q3) terminal plasma half-life. Note that the active metabolite of TAF, tenofovir 
> diphosphate, has a half-life of 150-180 hours within PBMCs.”

Source: [BIKTARVY: Prescribing information, page 22, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=22)

Note: Each row of Table 4 lists values in header order: bictegravir (BIC), emtricitabine (FTC), then tenofovir alafenamide (TAF).

## Related pages
- [Medical information: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide): HIV-1 infection](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection)
- [Indication](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/safety)
- [Specific populations](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/guidelines)
